Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.

Infigratinib treatment resulted in a statistically significant increase in height velocity in children with achondroplasia over 52 weeks, but the clinical relevance of this change remains to be fully understood.

Summary and findings

This study measured the effects of infigratinib on annualized height velocity in children with achondroplasia over 52 weeks. A total of 114 children aged 3 to 17 were randomized to receive either infigratinib at 0.25 mg/kg or placebo. The study reported a significant increase in height velocity in the infigratinib group compared to placebo.

Abstract

<h4>Background</h4>Achondroplasia is a genetic skeletal condition caused by <i>FGFR3</i> pathogenic variants. Infigratinib, an oral FGFR1-3 tyrosine kinase inhibitor, down-regulates key pathways in the pathogenesis of achondroplasia.<h4>Methods</h4>In this phase 3, multicenter, double-blind, placebo-controlled trial, we randomly assigned children with achondroplasia (3 to 17 years of age) in a 2:1 ratio to receive infigratinib (at a dose of 0.25 mg per kilogram of body weight) or placebo once daily for 52 weeks. The primary end point was the change from baseline in the annualized height velocity in the infigratinib group as compared with the placebo group at week 52. Key secondary end points were the change from baseline in the height z score and in the upper-to-lower body segment ratio at week 52. The primary analysis evaluated the treatment effect at week 52 in the full analysis population, with missing data handled with a prespecified imputation approach.<h4>Results</h4>In all, 114 patients underwent randomization: 75 patients to receive infigratinib (with 1 withdrawal before treatment) and 39 patients to receive placebo. The difference between infigratinib and placebo in the least-squares mean change from baseline to week 52 was 1.74 cm per year (95% confidence interval [CI], 1.31 to 2.17; P<0.001) for the annualized height velocity, 0.32 (96% CI, 0.23 to 0.41; P<0.001) for the height z score, and -0.02 (96% CI, -0.06 to 0.01) for the upper-to-lower body segment ratio. Adverse events occurred in 71 of 74 patients (96%) in the infigratinib group and in 37 of 39 patients (95%) in the placebo group; serious adverse events occurred in 4 of 74 patients (5%) and 1 of 39 patients (3%), respectively. No serious adverse events or adverse events leading to treatment discontinuation were considered by the investigator to be related to infigratinib or placebo.<h4>Conclusions</h4>In children with achondroplasia, treatment with once-daily oral infigratinib for 52 weeks resulted in a significantly greater increase from baseline in the annualized height velocity than placebo. (Funded by BridgeBio Pharma; PROPEL 3 ClinicalTrials.gov number, NCT06164951; EudraCT number, 2023-506130-67.).

Limitations

Not reported in abstract.

Elsewhere in the MGF (Mechano Growth Factor) corpus